Clinical Trial Update: Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial of TAS0953/HM06, a RET inhibitor, in adults with RET-altered advanced solid tumors including non-small cell lung cancer; the study is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• TAS0953/HM06

Snippet

Sponsor: Taiho Pharmaceutical Co., Ltd. | Conditions: RET-altered Non Small Cell Lung Cancer, RET-altered Solid Tumors | Phase 1, Phase 2 | Status: RECRUITING